POSTS TAGGED AS drug development

Autonomous Flexing Artificial Muscle

April 12, 2022 | | Posted in Newsletter

An Autonomous Chemically Fueled Artificial Protein Muscle
From Albert-Ludwigs-Universitat, Freiburg, Germany: “Herein, an artificial protein muscle is introduced, exerting rhythmic autonomous [MORE]

The Structure of Every Known Protein

April 12, 2022 | | Posted in Newsletter

DeepMind says it will release the structure of every protein known to science
“Back in December 2020, DeepMind took the world [MORE]

Cartilage on a Chip

December 24, 2019 | | Posted in Newsletter

”Researchers from the Polytechnic University of Milan and the University Hospital of Basel have developed a microfluidic chip containing cartilage, which [MORE]

Precision Lab Pathology for Targeted Therapies

January 9, 2018 | | Posted in Newsletter

Medical Laboratory Scientist US NIH
In the past three years, 25 new drugs have been FDA approved which target specific genetic [MORE]

Venom “Milking” Scorpion Robot

August 22, 2017 | | Posted in Newsletter

Milking scorpions for their venom may be one job lab technicians are happy to give up to robots. And such [MORE]

Synthetic Biotic

December 20, 2016 | | Posted in Newsletter

Sometime in 2017, a Cambridge, MA company, Synlogic, plans to carry out the first clinical trial using synthetic biology—which in [MORE]

Artificial Bioenzymes

August 23, 2016 | | Posted in Newsletter

Artificial Metalloenzyme
The noble metal indium, with its 49 electrons, is not found in living systems and thus assumed not to [MORE]

Millennium Prize for “Directed Evolution”

June 7, 2016 | | Posted in Newsletter

Frances Arnold Receives Millennium Prize
In directed evolution, bioengineers subject a gene to repeated mutagenesis in order to create an array [MORE]

3-D View of NMDA Receptor

August 19, 2014 | | Posted in Newsletter

Crystal Structure of NMDA
Like Rosalind Franklin’s image of the DNA molecule, an x-ray crystallographic picture of the NMDA receptor 9N-methyl-D-aspaeate) [MORE]

Big $ R&D Spenders

January 13, 2009 | | Posted in Newsletter

Genetic Engineering & Biotechnology News reported recently that GSK’s deal with Actelion, worth almost $3.2 billion, for Actelion’s insomnia drug [MORE]